BioSpace News Archive

Drug Development

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

PDS Biotechnology Corporation today announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer achieved its preliminary objective response benchmarks.

February 2, 2022

·

7 min read

Biotech Bay

Bolt Biotherapeutics to Participate in Upcoming February 2022 Conferences

Bolt Biotherapeutics announced that management will present at two upcoming conferences in February.

February 2, 2022

·

1 min read

Drug Development

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

ABVC Biopharma, Inc. today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.

February 2, 2022

·

4 min read

Deals

Daxor Corporation Commences Trading on The NASDAQ Capital Market

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it commenced trading on the NASDAQ Capital Markets as of today, February 2, 2022.

February 2, 2022

·

4 min read

Pharm Country

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

BioRestorative Therapies, Inc. today announced that the Japanese Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem ® Program.

February 2, 2022

·

3 min read

Business

Stryker declares a $0.695 per share quarterly dividend - Feb 02, 2022

Stryker announced that its Board of Directors has declared a quarterly dividend of $0.695 per share payable April 29, 2022 to shareholders of record at the close of business on March 31, 2022, representing an increase of 10.3% versus the prior year and unchanged from the previous quarter.

February 2, 2022

·

1 min read

Drug Development

AARDVARK THERAPEUTICS, INC., ANNOUNCES THE INITIATION OF ENROLLMENT FOR THREE PHASE 2 CLINICAL TRIALS OF ORAL ARD-101

Aardvark Therapeutics, Inc. announced today the initiation of enrollment in three Phase 2 studies with the company’s lead drug ARD-101, a first-in-class small molecule bitter taste receptor (TAS2R) pan-agonist.

February 2, 2022

·

3 min read

BioMidwest

Zeus Launches PTFE Sub-Lite-Wall® Multi-Lumen Tubing for Steerable Catheters

Zeus, the global leader in advanced polymer solutions, announced that it has added PTFE Sub-Lite-Wall® multi-lumen tubing to its product portfolio.

February 2, 2022

·

3 min read

Biotech Beach

ARS Pharmaceuticals, Inc. to Share New Data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

ARS Pharmaceuticals, Inc., will share new data on neffy highlighting our innovative intranasal treatment of type 1 severe allergic reactions including anaphylaxis at the American Academy of Allergy, Asthma and Immunology 2022 annual meeting in Phoenix, Arizona, February 25-28.

February 2, 2022

·

3 min read

Business

Mission Bio Transfers First Tapestri GMP-Ready CGT Assay to Avance Biosciences for Cell-Based Therapies

Mission Bio , the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced today the first tech transfer of a clinical trial-ready cell and gene therapy (CGT) assay from its Tapestri Platform to Avance Biosciences, Inc.

February 2, 2022

·

4 min read